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Introduction
Patient and public involvement (PPI) is recommended from 
the earliest research stages through to dissemination of the 
indings1–6. In the UK, INVOLVE3 states that research should be 
done with and by patients, but what does this mean for research-
ers and patient partners when starting a study? International 
resources are available (Box 1) and six UK PPI standards are being 
tested to see if they work in practice7. Table 1 summarises 
on-line guidance for research applications to international govern-
ment funding programmes that endorse involving patients and the 
public. Language varies internationally and is evolving as patients 
take a more central role in deciding what research is done and 
how. Box 2 provides some deinitions which are derived from the 
INVOLVE jargon buster8 and international resources (Table 1). 
PPI includes patients, potential patients, families, carers, patient 
groups and members of the public who use or have access to 
health and social care services3. We refer to this broad group as 
‘patients’ to distinguish them from clinicians and academics. This 
is consistent with Canadian guidance, which deines ‘patients’ 
as ‘an overarching term inclusive of individuals with personal 
experience of a health issue and informal caregivers, includ-
ing family and friends’9. However, ‘patients’ may include people 
who do not describe themselves in this way. People may self-
care for their condition and general public contributions can add 
value to research questions. Other relevant international terms, 
for example stakeholder involvement, consumer involvement, 
knowledge user engagement and patient orientated research 
are described in Supplementary File 1, Section A.
PPI is put into practice through patients discussing, helping 
to make decisions and occasionally doing research in order to 
enhance study relevance, design, conduct and governance. There 
is no ‘one-size-its-all’ approach. Flexibility is required to tailor 
patient involvement to the topic, research question, methods and 
resources available. This article describes steps that research-
ers and patient partners can follow when preparing a research 
funding application (Box 3). We refer throughout the arti-
cle to an illustrative example of a researcher who wants to do a 
study to improve outcomes for patients with migraine, and we 
provide examples from the literature and authors’ experiences.
Steps for how to involve patients and the public 
when applying for research funding
Understand what patient and public involvement is
At the outset, it is important to understand the theory 
underpinning PPI. In depth reviews and discussion of theory 
are available1,4,10–13 and suggest that, depending on the circum-
stances, PPI will: 
-    ensure that the research questions and outcomes really 
matter to patients
-    provide perspectives that complement or challenge those 
of researchers and clinicians
-    make research more relevant to the people whom it is 
designed to beneit
-    ensure that proposed research will be acceptable to 
patients so that they will be willing to participate
-   improve the quality of research
-    offer lay knowledge that is either independent for the 
purpose of governance, or speciic to the focus of study to 
enhance its design or conduct
-    make research more equitable and ethical, particularly 
when publicly funded
-   improve dissemination to reach wider lay audiences
-    increase the likelihood that research will be implemented 
into everyday practice and impact on patient care
-   enable patients to feel that their voice matters.
All of the above could reduce research waste14–16 if PPI is put 
into practice in ways that ensure that research is meaningful, 
acceptable, ethical and useful.
How does patient involvement differ from patient 
participation in research?
Patient perspectives can be sought through patient involvement 
and through patients participating in surveys, interviews or 
focus groups to provide data for others to analyse, interpret and 
act on. The authors have observed that in grant applications and 
study protocols, PPI is often conlated with qualitative research 
or patient opinion surveys. Collecting data from patients can be 
important to gain diverse or representative views, but it is dif-
ferent from PPI and both are often needed (Table 2). Discussion 
with patients at a workshop can seem similar to collecting data 
in a focus group, because both involve listening to patients’ per-
spectives, but the context and outcomes from listening differ. PPI 
means that researchers are in a continuing and reciprocal relation-
ship with patients and make decisions with them about the research. 
In qualitative research, researchers listen to patients in order to 
Box 1. Useful resources for patient and public involvement (listed alphabetically)
International endorsement of public and patient involvement in research
Australian Government National Health and Medical Research Council: Consumer and Community Involvement: https://www.nhmrc.gov.
au/research/consumer-and-community-involvement
Australian Government National Health and Medical Research Council: Statement on Consumer and Community Participation in Health 
and Medical Research (the Statement on Participation): https://www.nhmrc.gov.au/guidelines-publications/r22
Canadian Institutes of Health Research, Strategy for Patient-Oriented Research (SPOR): A coalition dedicated to the integration of 
research into care: http://www.cihr-irsc.gc.ca/e/41204.html
Cochrane Consumer Network. Statement of Principles for Consumer Involvement in Cochrane: http://consumers.cochrane.org/news/
statement-principles-consumer-involvement-cochrane
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Cochrane Training. Involving People learning resource relating to systematic reviews, developed by the ACTIVE (Authors and Consumers 
Together Impacting on eVidencE) project: http://training.cochrane.org/ACTIVE
European Patient Academy (EUPATI) is a network of European National Platforms which supports the integration of patient involvement 
across the entire process of medicines research and provides training. This includes the pharmaceutical industry and regulatory agencies. 
https://www.eupati.eu/
European Health 2020 Strategy calls for civil society engagement to improve health: http://www.euro.who.int/en/publications/abstracts/
health-2020-a-european-policy-framework-supporting-action-across-government-and-society-for-health-and-well-being
Gordon and Betty Moore Foundation and The American Institutes for Research: A roadmap for patient and family engagement in health 
and research: http://patientfamilyengagement.org/
Health Technology Assessment International Patient and Citizen Involvement: www.htai.org/interest-groups/patient-and-citizen-
involvement/
Nufield Council on Bioethics (2012) Emerging biotechnologies: technology, choice and the public good: http://nufieldbioethics.org/
project/emerging-biotechnologies/
Ottawa Charter for Health Promotion. World Health Organisation 1986: (http://www.who.int/healthpromotion/conferences/previous/ottawa/
en/index1.html)
Patient Centered Outcomes Research Institute (PCORI) standards: https://www.pcori.org/research-results/about-our-research/research-
methodology
PCORI Engagement Rubric: https://www.pcori.org/sites/default/iles/Engagement-Rubric.pdf
The European Group on Ethics in Science and New Technologies. (2015). Opinion on the ethical implications of new health technologies 
and citizen participation. Europa: https://ec.europa.eu/research/ege/pdf/opinion-29_ege_executive-summary-recommendations.pdf
US Department of Health and Human Services: Public Involvement with the National Institutes of Health: https://www.nih.gov/about-nih/
what-we-do/get-involved-nih/public-involvement-nih
Key UK-based resources and organisations
Healthtalk.org. Patient and public involvement in research: personal stories of patient involvement in research: http://www.healthtalk.org/
peoples-experiences/medical-research/patient-and-public-involvement-research/topics
INVOLVE: supports active public involvement in NHS, public and social care research. Funded by NIHR. http://www.invo.org.uk/. There are 
useful pages on ‘Budgeting for Involvement Guidance’: http://www.invo.org.uk/wp-content/uploads/2014/11/10002-INVOLVE-Budgeting-
Tool-Publication-WEB.pdf and an Involvement Cost Calculator: http://www.invo.org.uk/resource-centre/payment-and-recognition-for-public-
involvement/involvement-cost-calculator/
invoDIRECT is a directory of organisations, networks and groups that support active public involvement in research and helps people to 
identify activity in their area of interest. http://www.invo.org.uk/communities/invodirect/.
invoNET is a network of people who are building the evidence knowledge and learning about public involvement in research: http://www.
invo.org.uk/communities/invonet/.
James Lind Alliance: bring patients, carers and clinicians together in Priority Setting Partnerships to identify and prioritise the top 
uncertainties, or unanswered questions, about the effects of treatments: http://www.jla.nihr.ac.uk/
National Co-ordinating Centre for Public Engagement (NCCPE) has sections for researchers (and others) to explore, support, plan and do 
public engagement. It runs training courses and helps Universities to engage with the public: https://www.publicengagement.ac.uk/
NHS Health Research Authority: protects and promotes the interests of patients and the public in health and social care research and has 
top tips on public involvement in grant applications: https://www.hra.nhs.uk/planning-and-improving-research/research-planning/public-
involvement/
NICE’s approach to public involvement in guidance and standards: a practical guide (2015): https://www.nice.org.uk/media/default/About/
NICE-Communities/Public-involvement/Public-involvement-programme/PIP-process-guide-apr-2015.pdf
NIHR Going the Extra Mile strategy: https://www.nihr.ac.uk/patients-and-public/documents/Going-the-Extra-Mile.pdf
NIHR Patient and Public involvement in research. https://www.nihr.ac.uk/patients-and-public/
NIHR Public involvement standards development: a project aiming to improve the quality and consistency of public involvement (PI) in 
research through the development and introduction of national standards: https://sites.google.com/nihr.ac.uk/pi-standards/home
NIHR Research design service: provides support to health and social care researchers across England on all aspects of developing a 
grant application including, research design, research methods, identifying funding sources and involving patients and the public. Their 
advice is conidential and free of charge: https://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/research/research-design-
service/
Patients active in research: A website promoting partnership between patient, carers, members of the public and medical 
researchers, including case studies of patient involvement in research and opportunities to take part in medical research: https://
patientsactiveinresearch.org.uk/
Patients included charters: provide entities with a means of demonstrating their commitment to incorporating the experience and insight of 
patients into their organisations by ensuring that they are neither excluded, nor exploited: https://patientsincluded.org/
People in research: helps researchers and research organisations to ind patients to work with and advertises opportunities for public 
involvement in NHS, public health and social care research: https://www.peopleinresearch.org/
Research Councils UK Concordat for Engaging the Public with Research: https://www.ukri.org/public-engagement/
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Table 1. International government research funding guidance that endorses patient and public involvement (accessed November 2017).
Government general 
research guidance*
Terminology* Application form specific guidance Key features of funding applications
Australian Government 
National Health and 
Medical Research Council 
(NHMRC): Guidelines on 
Consumer and Community 
Participation in Health and 
Medical Research endorse 
consumers right to make 
contributions 
Consumer and 
Community 
Involvement 
 
Consumer and 
Community 
Participation
NHMRC advice and instructions to applicants: https://www.nhmrc.gov.
au/book/nhmrc-advice-and-instructions-applicants-2017/nhmrc-advice-
and-instructions-2017 
Indigenous populations: 
https://www.nhmrc.gov.au/book/nhmrc-funding-rules/section-b-project-
grants/b-attachment-d-guidance-applicants-address-criteri
Mandatory Plain English Summary. 
Consumer and community engagement sections are not always mandatory and 
applicants can decide ‘if applicable’. 
There is either a form section to complete which asks applicants to enter each 
community engagement activity separately or instructions to upload either a one 
or two page document. 
Fellowship applications require information about community engagement and 
participation for the previous 5 years or 10 years. 
Some forms have ‘if applicable’ sections which ask applicants to describe: a) how 
participants will have access to their own results and how the researchers will be 
accountable to participants for the overall results of the research: b) how they will 
ensure consumers are involved in the research and how they will communicate 
results to participants and the community.
Canadian Institutes of Health 
Research (CIHR), Strategy 
for Patient-Oriented Research 
(SPOR) Framework. Patient, 
Citizen and Knowledge User 
Engagement in research 
should be meaningful 
throughout the research 
process, to inform research 
planning and design.
Patient 
Orientated 
Research 
 
Patient 
engagement in 
research 
 
Citizen 
engagement in 
research 
 
Knowledge user 
engagement.
Current Opportunities: https://www.researchnet-recherchenet.ca 
Index of funding related forms: 
http://www.cihr-irsc.gc.ca/e/797.html 
Some application forms do not mention patient/citizen engagement, e.g. 
secondary analysis of existing datasets.
SPOR funded opportunities 
Mandatory research activities relating to the SPOR Framework, e.g. patients 
engaged as partners; focus on patients’ priorities; patients must play a key role 
in a multi-disciplinary team; a minimum of one Principal Applicant or Principal 
Knowledge User must be a patient; a workshop, roundtable, public lecture or 
citizen/patient engagement forum. A patient engagement plan is required 
Funding: applies a 1:1 matching formula with non-federal government partners. 
Applicants can request consultant fees for patient engagement experts and costs 
to facilitate engagement such as compensation, incentives, and the development 
of orientation and training. 
Non SPOR funding opportunities 
A lay summary is not always required. Some forms ask applicants to provide a 
Knowledge/ Technology Users (KTU) plan with activities that will translate the 
research results outside the academic environment. 
Funding may be available for indigenous populations. ‘Costs related to community 
mobilisation and engagement, including culturally relevant promotional items 
such as, tobacco, cloth, and cash reimbursements (in a method acceptable 
to the individual or community being reimbursed) to compensate community 
participation; and contracts and/or consultant fees for knowledge translation and 
communication activities for Elders, community members, and other Knowledge 
Holders involved in activities related to the Indigenous community’.
European Research 
Commission. Horizon 2020 
“Better Research for Better 
Health” https://ec.europa.
eu/programmes/horizon2020/
sites/horizon2020/iles/SPH_
VisionPaper_02062016.pdf
Involving 
citizens, end-
users and the 
public sector. 
 
Citizen Science. 
 
Multi-
stakeholder 
approach. 
 
Public 
engagement. 
 
Co-design.
‘Science with and for society’ is one of ive main priorities in the Horizon 
2020 Online Manual for applicants: http://ec.europa.eu/research/
participants/docs/h2020-funding-guide/index_en.htm 
Science with and for society http://ec.europa.eu/research/participants/
data/ref/h2020/wp/2018-2020/main/h2020-wp1820-swfs_en.pdf
Form requirements vary according to the funding call. 
Involving patients and citizens is recommended and new approaches are 
advocated. 
Citizen science is supported at all stages of research and innovation, with co-
design speciically mentioned. 
Current funding facilitates the establishment of self-sustaining ecosystems for 
citizen science that will continue beyond the duration of the funds. Guidance 
encourages institutional changes to sustain new forms of citizen involvement in 
research and innovation decision making.·½»ʼÅ¼ʹʼ
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Government general 
research guidance*
Terminology* Application form specific guidance Key features of funding applications
UK Health and Social Care 
Act 2012 endorses public 
and patient involvement: 
http://www.legislation.gov.
uk/ukpga/2012/7/contents 
UK Research Councils 
Concordat for Engaging the 
Public with Research. 
 
UK National Institute of 
Health Research (NIHR) 
supports Patient and Public 
Involvement in research. 
NIHR Going the Extra Mile 
strategy. 
NIHR standards for 
public involvement are in 
development.
Public 
Engagement 
 
 
 
 
 
 
 
Public and 
Patient 
Involvement 
(PPI) 
 
Co-production.
The Medical Research Council funds public engagement activities 
https://www.mrc.ac.uk/research/public-engagement/  
‘Pathways to Impact’ covers public engagement activities https://www.
mrc.ac.uk/funding/guidance-for-applicants/2-the-application/#2.2.5 
 
 
 
 
 
Application form guidance has a section on PPI: https://www.nihr.ac.uk/
funding-and-support/documents/current-funding-opportunities/hta/HTA-
Full-Guidance-Notes.pdf 
Extensive guidance on budgets and a cost calculator are on the 
INVOLVE website (www.invo.org.uk).
All Research Council funding applications have an Impact Summary, which is for 
the public domain. In addition there is a two page attachment called ‘Pathways to 
Impact’ where applicants are asked what they will do to make beneiciaries aware 
of the research and how they will beneit. Impact generating activities are two-way 
and start when developing the application: https://www.publicengagement.ac.uk/
plan-it/funding/public-engagement-and-pathways-impact. Applicants can request 
project-speciic resources and are asked justify costs. Training costs, specialists 
in public engagement, materials, venue costs and travel expenses are eligible for 
full economic costing. 
There are mandatory PPI sections and a lay summary in NIHR forms. If applicants 
are a member of the public, patient /service user or carer, they are asked to 
provide their knowledge, skills and experience instead of a CV. PPI sections ask: 
Were patients and the public actively involved in identifying the research topic or 
prioritising the research questions? Were patients and the public actively involved 
in preparing this application? Please indicate the ways in which patients and the 
public will be actively involved in the proposed research. 
Eligible costs include: payment, rewards, expenses, costs of activities and 
involvement stafing to support, co-ordinate and facilitate involvement. 
Payment options include fees, vouchers, donations, gifts, funding for training, 
honorary appointments. Expenses include travel, subsistence, child care/carer 
costs, personal assistants, overnight accommodation and home ofice costs. 
Involvement activity materials, venues, catering and conference fees can be 
included, as well as translation, interpretation and support for people with 
impairments. The form requires full economic costs for PPI and justiication of 
costs. There is no upper limit and external peer review guides funding decisions.
US Department of Health 
and Human Services: Public 
Involvement with the National 
Institutes of Health. 
 
Patient Centered Outcomes 
Research Institute (PCORI) 
standards.
Patient 
partnerships 
 
Patient-
Centered 
Outcomes 
 
Patient 
engagement 
 
Co-learning 
 
Reciprocal 
relationships.
Pre-award user guide: https://www.pcori.org/sites/default/iles/PCORI-
Online-Pre-Award-User-Guide.pdf 
PCORI Engagement Rubric for the entire research process includes a 
inancial compensation framework https://www.pcori.org/sites/default/
iles/Engagement-Rubric.pdf
Researchers partner with patients and other stakeholders from the planning 
stages through to dissemination of indings to answer patient-centered questions. 
Focus on outcomes that matter to patients. 
For some highly technical and methodological projects, patients may not make 
appropriate partners. 
A public abstract and an engagement plan covering three stages: planning, 
conduct and dissemination are required. Applicants are expected to demonstrate 
how they meet the six PCORI patient engagement principles in their work: 
reciprocal relationships; co-learning, partnerships, transparency, honesty and 
trust. 
Information is required that supports how patient informants and people 
representative of the population of interest input into decisions about outcomes. 
Information may come from meetings, surveys or published literature. 
Applicants are asked to give a detailed budget aligned with engagement 
activities as outlined in the engagement plan. This includes compensation for 
patient time and expenses incurred (travel, accommodation, parking, childcare, 
respite or caregiver expenses. special needs, phone, internet). Applicants are 
advised not to let cost be a barrier to patient engagement and to include a staff 
budget to support patient engagement: e.g. recruitment, training, mentoring, co-
ordinating and for engagement events.
*Websites for international research guidance, deinitions of terms and additional information are provided in Box 1, Box 2 and Supplementary File 1
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Box 2. Terminology
Some acronyms for involving people in research
PPI –Patient and Public Involvement: http://www.ukcrc.org/patients-and-public/. In the European Research Commission, PPI means Public 
Procurement of Innovative Solutions.
PPIE – Public Patient Involvement and Engagement: https://www.nihr.ac.uk/about-us/documents/PPIE-Leadership/NIHR-PPIE-Strategy_
2018-19.pdf
PIA – Public Involvement Activities17
PCORI – USA Patient-Centered Outcomes Research Institute http://www.pcori.org/program/engagement
NIP – National Involvement Partnership which includes the 4PI – Principles, Purpose, Presence, Process, Impact which are national 
involvement standards https://www.nsun.org.uk/FAQs/4pi-national-involvement-standards
Definitions
Deinitions are derived from the INVOLVE jargon buster8 and international resources in Table 1 and Box 1.
Participating in research describes people who have consented to provide data for analysis to further knowledge (participants). Historically 
participants were referred to as ‘subjects’ of research. ‘Participatory research approaches’18 is used as an umbrella term which covers 
‘participatory action research’19,20, co-design21,22 and co-production of research23,24. In our opinion, a more suitable umbrella term is 
‘partnership approaches’.
Involving. INVOLVE3 deines public involvement in research as research being carried out ‘with’ or ‘by’ members of the public rather than 
’to’, ‘about’ or ‘for’ them and states that the term ‘public’ includes: 
•   Patients, potential patients, carers
•   People who use health and social care services
•   People from organisations that use services
INVOLVE makes a distinction between the ‘public’ and people who have a professional role in health and social care.
The European Union (EU) website refers to ‘citizen Involvement’ which includes upstream priority setting, inluencing funding decisions to 
a more direct downstream involvement of citizens and patients in the use and application of medical knowledge and information. It covers 
both active citizens who engage from a position of agency as well as those unaware of their contribution25, ‘Citizen Science’ is used as an 
EU umbrella term which is envisioned as various forms of public engagement with science as a way to promote responsible research and 
innovation.
Partnership is when people who get actively involved in research have a relationship that involves mutual respect and have an equal voice. 
This contrasts to someone who is consulted occasionally. PCORI consider that the principle is demonstrated when time and contributions 
of patients and stakeholder partners are valued and demonstrated in fair inancial compensation, as well as in reasonable and thoughtful 
requests for time commitment. When PCORI studies include priority populations, the research team is committed to diversity across all 
project activities and demonstrates cultural competency, including people with disabilities, when appropriate.
Reciprocal Relationships is one of six PCORI engagement principles. They are demonstrated when the roles and decision-making authority 
of all research partners, including patients, are deined collaboratively and clearly stated.
Collaborating is active, on-going involvement in the research process; however, responsibilities are not equally shared like they are in 
partnerships. Patients may be co-applicants on a grant application, take part in an advisory group or work with researchers to design, 
undertake and/or disseminate the results of a research project.
Engaging is a term used in the USA by PCORI and the Canadian Institutes of Health Research. PCORI deine engagement as meaningful 
involvement of patients, carers, citizens, clinicians and other healthcare stakeholders in the topic selection, design, conduct and 
dissemination of research indings. There are six PCORI patient engagement principles: reciprocal relationships; co-learning, partnerships, 
transparency, honesty and trust. The UK National Co-ordinating Centre for Public Engagement in Research (https://www.publicengagement.
ac.uk/do-it) deines public engagement as: ‘the myriad of ways in which the activity and beneits of higher education and research can 
be shared with the public. Engagement is by deinition a two-way process, involving interaction and listening, with the goal of generating 
mutual beneit’.
Devolving is to place decision making in the hands of patients or communities, for example, a community development approach26.
Consulting is gaining feedback from patients and communities through e.g. meetings, on-line fora, workshops. The role is considered to be 
relatively passive when compared to ‘engagement’
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Action Research brings about improvement or practical change. A group of people who know about a problem work together in a 
‘partnership’ to develop an idea about how it might be resolved. They then go and test this idea. The people who take part in the testing 
provide feedback on their experiences. It has key tenets20: 
-   Flexible planning – the detailed content and the direction of the research are not determined at the outset
-    Iterative cycles with all involved to i) decide what the problem is, ii) decide an action iii) take action iv) learn the lessons from the 
action v) reconsider the problem and repeat the cycle
-   Subjective meanings of those involved determine the content, direction and measures of success of the research
-   The research simultaneously improves the situation
-   The unique and ever changing social context is taken into account
Co-production means people who use services, members of the public and professionals working together in a ‘partnership’ to produce 
research or service improvement. It is an umbrella term for a concept that means coming together to ind a shared solution. ‘Co-‘ can be put 
before speciic research tasks like ‘co-design’, ‘co-build’ and ‘co-construct’. Co-production27 covers the whole research process from idea 
to dissemination of indings in order to change practice.
Co-learning is a term used by PCORI, where the goal is to help patients or other partners to understand research processes. The goal is 
not to turn patient partners into researchers. PCORI use the term in the context of ‘reciprocal relationships’, where all research partners 
including patients learn collaboratively. https://www.pcori.org/sites/default/iles/Engagement-Rubric.pdf
Box 3. Overview of how to involve patients in research
A clinician wants to involve patients in a trial of treatment for migraine. Here are steps for involving patients when preparing a research 
funding application.
1.   Understand what patient and public involvement (PPI) is and the different approaches 
i.    refer to research funder guidance about public and patient involvement because it varies internationally and is rapidly 
evolving
ii.   understand how patient involvement differs from patients participating in research
iii.  use language precisely because it varies internationally
2.   Find out what research questions are priorities for patients 
i.  search the internet for existing work on patient priorities and ask patient organisations
ii.    if patient priorities are unknown, discuss this with your proposed funder and consider how you might ill the gap to 
progress your research
iii.  prioritise patient-centered outcome measures and ind acceptable research methods
3.   Identify patients (not your own), charities and/or patient groups to potentially involve as early as possible 
i.    consider identifying a professional or lay link worker, perhaps through a charity or a university or hospital patient 
advisory group
4.   Select patients and/or patient groups to be involved in your study 
i.   consider equity of opportunity, unheard perspectives and health inequalities
ii.  consider the potential for bias and conlicts of interest
5.   Negotiate and agree an approach, tasks and responsibilities at an early stage 
i.   consider which approach will add value and rigour to your research
6.   Negotiate appropriate funding to pay patients, reimburse expenses, fund activities and staff time to facilitate patient involvement
7.   Consider whether training will be required for the proposed roles and responsibilities
8.   Consider whether patients or patient groups will ‘do’ any research 
i.   do they have appropriate skills?
ii.   how will they add value and are there risks?
iii.  will they be employed?
iv.  who will mentor and provide supervision?
9.   Consider the ethical and research governance implications for involving patients in your study
10.  Involve patients in writing the grant application
11.  Involve patients to plan future reporting and dissemination of your research
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Table 2. Patient participation and patient involvement in research: Methods compared.
Research 
methods
Qualitative and survey research:patients are study particpants 
who provide data (text or numerical) on their perspectives to 
inform research team decisions.
Public Patient Involvement:patients actively contribute through discussion to 
decisions about research priorities, design, relevance, conduct and governance 
from study conception to dissemination
Strengths Limitations Strengths Limitations
Who 
contributes? How 
are they selected 
to represent the 
views of larger 
populations and 
to meet the aims 
and objectives of 
the research?
Sampling strategies are carefully 
constructed to recruit patients e.g. 
for speciic characteristics, maximum 
diversity or a representative sample. 
Usually participants have little 
experience of research.
Can be resource intensive. 
Under-privileged groups 
can be hard to recruit. When 
to stop sampling is seldom 
straight forward.
Individuals provide their own patient 
experience and perspective. Larger charities 
have well-developed infrastructure, provide 
equity of opportunity and empower patients 
to provide meaningful contributions to 
multiple projects. Active social media sites 
access a wide range of perspectives. 
Patients may undertake training for a PPI 
role.
Selection processes, characteristics 
and conlicts of interest are seldom 
reported. Some PPI groups lobby 
politicians or have inluential networks 
with key decision-makers. Patients can 
become professionalised, exclusive and 
immersed in an academic establishment. 
How many 
contributors are 
required (sample 
size)?
Variable and lexible in order to answer 
emergent research questions. Quality 
standards apply. Small samples may 
be appropriate if there are qualitative 
evidence syntheses and few residual 
uncertainties. Larger representative 
samples are required where little 
research exists, to build theory, or if 
there are multiple uncertainties.
Recruitment problems, lack 
of resources, limited sites, or 
convenience sampling can 
introduce bias. Premature 
conceptual closure can 
occur and is more likely 
when methods tend towards 
consensus: e.g. focus 
groups, workshops, Delphi 
or nominal group techniques.
There is little guidance, so researchers can 
decide and operate within their available 
resources. INVOLVE (http://www.invo.org.uk/) 
state at least two patient contributors attend 
team meetings.
Individuals cannot fulil the role of 
representing all patients and public 
perspectives. The resources may 
limit the number and timing of patient 
contributions.
How do they 
contribute to 
each stage: 
e.g. research 
questions, 
design, 
recruitment, 
outcome 
selection, data 
collection, 
process 
evaluation, 
dissemination, 
reporting and 
implementation?
Focused open research questions e.g. 
about experience of an intervention/
recruitment. Usually at one time point.  
Qualitative researchers have highly 
skilled attention to non-verbal 
communication, contradictions, 
language and context. Researchers 
use the indings to inform decision-
making. The patient perspective may 
or may not inform the research design 
and conduct.  
Reporting guidelines apply: http://www.
equator-network.org
Researcher skills vary. 
Closed questions asking 
“what” rather than “how” or 
“why” will limit data quality, 
prime responses and can 
bias indings. Analysis by 
inexperienced researchers 
can generate “common 
sense” or “so what” 
critiques rather than skilled 
interpretation.
Range from limited involvement at steering 
groups to full engagement as a grant 
co-applicant satisfying the responsibilities 
set out by the funder. Methods range 
from informal discussions to partnership 
research approaches e.g. action research, 
co-production. Patient partnerships imply 
recognition, mutual respect, commitment 
and equity in decision-making. Patients with 
appropriate skills may be involved in data 
collection, analysis or interpretation. There 
are guidelines for using PPI in trials28 and PPI 
reporting29.
Protocols and reports often lack 
transparency for how PPI is 
operationalised and impacts on decision 
making. Grant-holder status may be 
inappropriate for patients with limited 
resources and can have opportunity 
costs, e.g. patients working for a charity 
may have less time for direct patient 
support. Views can be undervalued. 
Alternatively views can lead research in a 
direction that proves counter-productive. 
Patients may experience regret or blame.
Ethics, funding 
and research 
governance.
Data collection and access require 
ethics committee approval to satisfy the 
Data Protection Act and Declaration 
of Helsinki (http://www.hra.nhs.uk). 
Participants are not usually paid but 
can be offered reimbursement for 
expenses, or a gift to recompense for 
time or travel. Sponsoring institutions 
apply research conduct and 
employment governance to ensure 
good practice.
Ethics committee approval 
for study protocols and 
subsequent amendments 
are time consuming, and 
should not be an a priori 
straight jacket that restricts 
change. Build lexibility into 
study protocols for iterative 
modiication of recruitment 
strategies e.g. if plan A does 
not work, state plan B and 
plan C in order to recruit the 
sample required.
Patient involvement where no data is 
collected, stored or accessed does not 
require ethics approval. UK patients are 
reimbursed for their time (http://www.invo.
org.uk/). There are agreements (of varying 
formality) about what will be undertaken. 
Conidentiality is expected. Patients are 
usually independent of academic institutions 
and funding bodies. Charities usually have 
their own ethics and governance policies. 
Build in lexibility for protocol change when 
using patient partnership approaches like 
co-production.
If patients recruit, provide, collect 
or analyse data, ethics approval is 
required. If patients do research usually 
undertaken by researchers, the sponsor’s 
research and employment governance 
procedures apply. Short term study 
funding can result in productive patient 
partnerships ending. Patient groups often 
use social media to seek views, which 
can pose risks for conidentiality and 
data protection. Patients should consent 
to how their contribution to research is 
reported and declare any conlicts of 
interest.
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improve their understanding of a topic. Focus group discussions 
or qualitative interviews are audio-recorded and transcribed. 
Researchers collate, analyse and interpret text data from 
carefully sampled patients to produce valid new knowledge 
and generate hypotheses. Qualitative and survey research have 
systematic methodological quality standards. However, the 
researcher holds the power and patients may express strong 
views which may not be reported. In any research, the PPI and 
the data collection to gain wider patient perspectives can be 
separate, combined or overlap in some study phases, or they can 
be completely integrated throughout (Figure 1). Any combina-
tion is possible (Supplementary File 2, Example 1). They are 
often combined and integrated in equitable partnership research 
methods like action research, and ‘co-‘ preixes to research 
terms, e.g. co-learning and co-production (Box 2).
Action research, co-design, co-learning and co-production
Action research historically precedes co-production and 
gathered momentum in the 1940’s as a community-led action 
in research initiative19,20,30. The UK National Institute of Health 
Research (NIHR) who fund research advocate co-production27 as 
a method of involving patients meaningfully from start to inish 
of the research process. Differences in deinitions (Box 2) are 
subtle, vary internationally and researchers may apply the 
approaches lexibly in practice. ‘Partnership approaches’ is used 
in this article as an umbrella term because it acknowledges the 
changing roles of patients beyond being ‘participants’ or ‘sub-
jects’. Partnership research methods involve patients, clinicians, 
academics and other relevant stakeholders as equal mutually 
respected partners in the research team. Being a patient part-
ner implies equal opportunity and equal voice. Equal power in 
decision-making is sometimes implied, however there are struc-
tural and economic power differentials between different types 
of partner in terms of pay, employment contracts, status and 
workplace environments. As language is evolving internationally 
it is more helpful to describe actual patient roles, tasks and 
responsibilities explicitly rather than use a label for an approach 
that is open to misinterpretation. For example, co-production27 may 
mean consulting patients regularly or patients may actively col-
lect and interpret research data. Terms like ‘Participatory Action 
Research’ confuse because the deinition of ‘participation’ in 
a study means to contribute data, rather than active involvement 
in research decisions. Partnership research teams decide who 
has access to participant level data, how to share data securely 
and how decisions will be made collectively. Partnership 
approaches can be resource intensive require leadership skills to 
balance equity of decision-making with a strong scientiic ration-
ale. Negotiation skills are required to accommodate different 
perspectives in order to reach consensus in a timely manner. An 
important limitation to consider is how the partnership approach 
is interacting with the intervention: for example action research 
can become an active intervention component (Supplementary 
File 2, Example 2).
When starting to design a study about migraine, understand 
how PPI will add value to the research and which uncertainties 
about patient perspectives might benefit from additional analysis 
of patient data from a survey or qualitative interviews.
Find out what research questions are priorities for patients
Many funders require researchers to justify that their research 
question addresses what is important to patients31–33. If a 
research question is of low priority to the people affected by the 
condition, or important outcomes are not considered, and/or the 
intervention in question is considered unacceptable to patients, 
then further research is wasteful11.
A starting point for researchers is to ind out if patients’ priori-
ties already exist for their topic. Many national and international 
organisations involve patients to identify and publish research 
priorities speciic to a healthcare condition. In the UK, the 
James Lind Alliance (JLA) speciically identiies and prioritises 
Figure 1. The interface between Public Patient Involvement (PPI), qualitative and survey research across all stakeholders in 
research.
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research questions for funders and there is a register34,35. JLA 
establish Priority Setting Partnerships which involve collabora-
tions between patients, carers and clinicians. The NIHR funds 
JLA advisors and the infrastructure, but a Priority Setting 
Partnership is responsible for its own funding. The JLA has 
a guidebook which provides step by step processes to identify 
research uncertainties and prioritise a top 10 list for different 
conditions36. Researchers are advised to evaluate how priorities 
were established and the rigour of processes, as priorities 
can change with time and some groups may not have had an 
opportunity to be involved.
If patients’ priorities are unknown, and a Priority Setting 
Partnership is not available, contacting the potential funder to 
discuss options may be helpful. When researchers plan bespoke 
methods to prioritise research, it is important to ind patients 
as soon as possible to identify the topic and reine the research 
question to ensure relevance. For example: work with a charity 
or a research organisation to conduct an on-line survey 
(Supplementary File 2, Example 3); advertise and run open 
public workshops with patients to rank research priorities; or ask 
participants in qualitative interviews what would make a differ-
ence, then construct research scenarios for them to ‘think aloud’ 
which one they would prioritise. Once patients have prioritised the 
research topic and questions, the next step is to prioritise the 
outcomes that matter, patient-centered outcome measures and 
identify acceptable research methods.
A first step for a researcher is to search the internet for key 
organisations and guidelines to see if patient research priori-
ties for migraine are available. If not, a researcher can contact 
migraine charities and talk to a potential funder to seek their 
advice.
Identify patients and/or patient groups to involve as early 
as possible
Researchers are advised to ind people to involve and to plan 
potential roles, responsibilities and tasks for their study as early 
as possible. Research teams may approach patients through 
formal patient groups, charities, community groups, Univer-
sity or Health and Social Care patient advisory panels, national 
directories such as ‘People in Research’37, invoDIRECT38, patients 
who are involved in producing guidelines like The National 
Institute of Health and Care Excellence39, or through personal 
recommendation or advertisement. See Supplementary File 2, 
Example 4. It is usually not considered appropriate to involve 
patients that members of the research team are currently 
providing clinical care to40. In the UK, InvoDIRECT38 provides 
an A-Z on-line resource of organisations, networks and groups 
that support PPI in health and social care research (Box 1).
Lay or professional coordinators or link people may help and 
different sources of patients may be used for different purposes. 
For example, a head ofice of a patient charity may be invited 
to nominate a person to join a study steering committee, whereas 
a local patient group may help to make recruitment materials 
appealing and easily understood. Participants in a preparatory 
survey, focus group or qualitative interview may be invited to 
volunteer for patient involvement in future research. The 
qualitative research and PPI then become synergistic.
A researcher wanting to study migraine could contact a char-
ity, their University or Health Service patient advisory panel 
or consult directories of patients who are interested in being 
involved in research. Invite a patient link worker to join the 
team who will co-ordinate wider patient involvement.
Decide who and how many patients to involve
As with any appointment, selection criteria for patients based 
on the research plan are useful to inform decisions. Decid-
ing the number of patients to involve in a study requires careful 
consideration. Two is the minimum number recommended by 
INVOLVE3, however international guidance is less speciic. 
The patient characteristics, skills and numbers will vary according 
to: 
-      the study design, e.g. several patients with diverse 
personal experiences of a health condition may be 
consulted about which outcomes will be measured in a 
trial41. Co-authors Arthritis Research UK expect patients 
to be involved in all applications including lab-based early 
phase research to develop new treatments
-      the prevalence of the condition, e.g. it may be challenging 
to identify two or more patients with rare conditions
-      the relevance and reach of a new intervention, e.g. adverts 
on Facebook for selected postcodes can identify rural 
and under-privileged urban perspectives
-      how much personal tailoring and choice is possible in 
the design of the research, e.g. two closely involved 
patients may advise the research team at meetings for 
a Cochrane Systematic Review, whereas many diverse 
patient groups may be consulted when prioritising 
research questions to improve migraine outcomes.
Consider equity of opportunity, unheard perspectives and 
health inequalities
Equity of opportunity for patients to be involved in research 
underpins UK guidance. The NIHR standards for PPI7 provide 
practical examples for how researchers can offer inclusive oppor-
tunities and sustain respectful, productive relationships. There is 
a danger that patient contributors are atypical, as the more con-
ident and inancially secure are more likely to volunteer. It can 
be easier to involve older, white and educated people, which can 
marginalise other perspectives. Health inequalities and equity 
are important when making research decisions42. Aim to ind 
patients who represent the demographic of those affected by the 
condition. It can be challenging to access ‘typical’ members of 
the target population for the speciic research question42–44. See 
Supplementary File 2, Example 5. An adult or child may be 
selected to represent their own views45 or, when the research 
involves children, vulnerable patients or patients with cognitive 
impairment, then a guardian, relative or carer may represent the 
patient’s views. A lack of resources can hinder recruiting some 
patients, such as those from ethnic minorities, the less privi-
leged and less literate. Yet this is important because they tend 
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to experience lower health status and poorer access to services. 
For these patients it can feel intimidating to meet researchers and 
attend meetings in a University. Alternative strategies include 
researchers going out into the community in order to build 
rapport and trust with patients on their own turf, which can 
then lead to discussions about research (Supplementary File 2, 
Example 1)46,47. An outreach model for patient involvement via 
a link coordinator (professional or lay) can help to access less 
heard perspectives (Supplementary File 2, Example 5)48. 
A useful guide for getting started and arranging a meeting 
with patients is available on the INVOLVE website49.
A charity partner might help a researcher to plan how patients 
on low-income or from ethnic minorities can contribute to 
a research study on migraine. Adverts, social media and 
attractive visual information in local newspapers and chemist 
shops may help.
Consider the potential for bias and conflicts of interest
PPI in research and political lobbying can co-occur and intro-
duce conlicts of interest with the potential to inluence 
research decisions in ways that have been under-researched50. 
Researchers are advised to consider sources of funding and 
afiliations of patient contributors, and to re-assess any arising 
conlicts of interest during their study.
Patients can work with research teams over many years, 
attend training courses and become a ‘PPI methodologist’ 
or expert individual or group. This has advantages and risks. 
Experienced patients can have an overview of a particular health 
condition that is invaluable. However, becoming embedded in 
a research team or an organisation can risk losing the ‘eye of the 
public’51. Researchers are advised to consider whether bias due 
to ‘group think’52 is possible. This is a risk in any established 
team, for either researchers or patients to become so familiar with 
the group or clinical area that they lose sight of fresh perspec-
tives. Selecting new untrained patients for a study can highlight 
researchers’ preconceptions and assumptions. However, this 
also has limitations, as it can be dificult for patients to under-
stand, question and challenge researchers when the language and 
culture are unfamiliar. Patients who have beneited from or expe-
rienced adverse events from a particular treatment can intro-
duce bias. Select patients to balance views, for example patients 
who have positive and negative outcomes from a new proce-
dure or treatment. It may add rigour to include qualitative or 
survey research to gain diverse and/or representative patient 
perspectives.
Throughout all stages of a study, researchers and patients 
make decisions that need to balance and prioritise evidence, 
personal experiences and competing values held at the individ-
ual, family, organisational, political, cultural and environmental 
levels. Rigour and quality standards for PPI in research are 
important to counter critics, as there is still some resistance to 
implementing PPI53.
A researcher is advised to consider conflicts of interest and 
sources of bias, for example links to industry or private 
companies. Seek to balance positive and negative patient 
experiences relevant to the study.
Negotiate and agree an approach, tasks and 
responsibilities at an early stage
Once patients are involved, it is advisable to agree clear 
boundaries about the scope of the role, speciic tasks and respon-
sibilities. Some lexibility is desirable to accommodate unex-
pected issues that can arise in research and there are grey areas. 
See Supplementary File 2, Example 6. The approach can be 
bespoke for each study or for each phase within a study12,17,44,48,54 
and can vary in the level of patient engagement, responsibility 
and control. Patients can contribute to three key functions: 
research decision-making; enhancing understanding of patient 
experience; and advising how to capture knowledge from other 
patients. For each function, a question to ask is: which method 
for involving people will add value and rigour? Example 7 
(Supplementary File 2) draws on the work of Gamble and 
Colleagues who have produced a useful list of tips for patient 
roles in clinical trials derived from a cohort study of 111 funded 
trials28.
Be realistic about what will be possible to achieve and the 
resources required3. A template for Terms of Reference is avail-
able on the INVOLVE website49. Terms of Reference acknowl-
edge the importance of mutual respect, practical communication 
issues and can be reviewed as the research progresses. Research-
ers may invite patients to propose ground rules for the length 
of time required to read and respond to emails and comment on 
documents, for mutual agreement. It is important for research-
ers to remember that patients may be managing ongoing health 
conditions which can be unpredictable. Patients value individual 
constructive and honest feedback about their contributions in 
order to learn, gain conidence and maintain motivation7.
At an early stage a researcher is advised to discuss roles and 
tasks involved in the migraine study. For example: help to design 
an appealing patient leaflet, recruit patients, attend project 
management meetings, interpret findings and present them to 
lay audiences.
Agree appropriate funding for patient involvement
International arrangements for supporting patient involve-
ment in research vary according to the funding opportunity. It is 
important for researchers to check current guidance for the fund-
ing call they are applying to and budgeting guidance is usually 
available (Table 1). Negotiate with patients the costs: payment 
for patient time, any special needs (e.g. childcare, hearing impair-
ment, translation services), training, reimbursement of travel and 
subsistence expenses. In addition, include costs for staff time to 
co-ordinate, support, train and facilitate patient involvement. 
Researchers are advised to spell out to patients the best case and 
worst case scenarios (e.g. delays to study start and inish), and 
what contributing to the study would and could involve. Some 
patients prefer to volunteer, others prefer cash payment or vouch-
ers. Consider patients who are less inancially secure. Patients 
may rely on beneits, part time work or retirement pensions, 
therefore consider how dificult it is to pay upfront for travel, to 
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scan travel tickets in order to claim research expenses or to have 
access to computers or printers to access documents for a meeting.
Preparatory PPI activity prior to submitting the grant 
application can pose a problem for researchers because funding 
for this is seldom available prior to a grant. Yet this is precisely 
when patients can have important impact on the study research 
question, design and plan. In England, the NIHR Research Design 
Service will provide small amounts of money to cover PPI at the 
design stage55. Some Universities fund generic patient partner-
ship panels (e.g. 56) to work with researchers who are seeking 
funding and larger charities can often help57.
When costing a study about migraine, negotiate sufficient funds 
to pay for the planned PPI activities, be realistic about the 
workload and the resources required and consider special needs.
Training for patients involved in research
Providing or offering training may or may not be appropri-
ate depending on the patient role and the purpose of training. 
Training may be desirable in order to undertake highly skilled 
roles like reviewing grant applications or sitting on independ-
ent trial steering committees. In particular, training in the prin-
ciples of evidence based medicine, with consideration of where 
and how patient stories it in evidence hierarchies may be use-
ful. Example 8 (see Supplementary File 2) provides some train-
ing programmes that support patient involvement in research. For 
patients new to a PPI role, support to develop their abilities and 
conidence to express their views and question researchers 
may be relevant. Many universities, research funders and 
charities provide learning and support activities.
There are many PPI tasks where training is not necessary, 
where a different perspective is what really matters and patient 
experience of a healthcare condition is the required exper-
tise. For example, when helping to choose important outcomes 
or advising on patient information or recruitment strategies, 
‘untrained’ patients may make particularly valuable contributions.
Patients doing research
Traditionally, academics with qualiications, experience and 
recognised research skills collect and analyse data. However, 
increasingly patients are helping to recruit participants, collect 
or analyse data and some UK grant application forms ask about 
this (Supplementary File 1, Section B). Such questions arguably 
prime researchers to think that all boxes should be ticked, without 
considering the implications. Only appropriately trained 
patients or lay people should undertake research. Shared experi-
ences of a condition can build trust, empathy and a bond which 
may help to recruit dificult to engage groups, for example children 
in care45. However, attention is required to individual expertise, 
training requirements, supervision and the scientiic rigour nec-
essary to execute high quality research. Patients may do research 
alongside researchers in partnership research methods58 and 
a paradigm of patient-led research is emerging facilitated by 
social media and digital technologies59. INVOLVE has a 
Patient-Led-Research-Hub to support patients who want to 
pursue their own research ideas38.
In the UK, any researcher accessing study participants who 
are NHS patients or staff requires a letter of access, sometimes 
referred to as a ‘research passport’, obtained from the NHS 
Research and Development ofices (Supplementary File 2, 
Example 9)60. If patients or lay people help to recruit participants 
to research, gain informed consent or collect, share or analyse 
data from individual or group discussions, qualitative research 
or surveys, then they are ‘doing research’ and there are poten-
tial governance implications for the sponsor of the research 
in terms of employment law, ethics, leave entitlement and 
indemnity. Researchers should not encourage patients to do 
research because it requires less resource, or because it obviates 
the need for relatively costly skilled researchers whilst 
simultaneously bypassing regulatory hurdles. Rather, research-
ers and patient partners can decide together whether patient 
researchers are appropriate and beneicial to speciic research 
projects.
Researchers wanting to study migraine may consider the 
pros and cons of patients doing aspects of the research and the 
governance issues.
Working together ethically
Consider how to work with patients ethically. PPI can be 
empowering for individuals and communities, but there are 
tensions and risks, including exploitation25, and the burden 
and resource implications can be considerable10. Some ethical 
principles for researchers to consider when involving patients 
in research include: 
-      avoiding discrimination, undue persuasion, excessive 
burden or creating a sense of obligation to be involved in 
the study
-     the distribution of power in research
-      valuing patient contributions and fair inancial 
compensation
-      conlicts of interest, research integrity and respect for 
intellectual property
-      the conidentiality of data and protecting anonymity of 
research participants
-     advancing science through honest and accurate reporting.
INVOLVE3 states that UK ethics committee approval is not 
required when patients advise research teams, prioritise research 
questions, make choices relating to design, share decision- 
making or disseminate research indings. However, there can 
be grey areas particularly in relation to deining ‘data collec-
tion’. NHS or University Ethics committee approval is required 
in the UK if personal information, i.e. data as deined in the Data 
Protection Act61, is collected, shared and stored for future analy-
sis and reporting. For iterative partnership research approaches 
like co-production, the current ethics committee processes 
create many challenges62. Researchers can request informed con-
sent from participants to share anonymised data with patient 
partners, so that they can be involved in analysis and 
interpretation as members of the study team.
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There are international differences in requirements for 
research ethical and governance approvals, and particular chal-
lenges with digital health research25 which are beyond the remit 
of this article. New EU General Data Protection Regulation63 
commenced in May 2018, and requires transparency about 
the source of personal data, the purpose and who data will be 
shared with.
Audio-recording of PPI meetings in order to write accurate 
but not verbatim minutes, does not require ethics committee 
approval. However, it does require at least verbal consent from 
all present at the start of the meeting and the recording should 
be destroyed as soon as the minutes are agreed. People should 
receive forewarning of the intention to audio-record, know the pur-
pose, what will happen to the recording and to the content, and 
be able to object or withdraw. If audio-recordings are stored for 
longer than is necessary, transcribed verbatim or if there is an 
intention to report or publish potentially identiiable quotations 
or content arising from PPI activities, then ethics committee 
approval is required. Ethics committees have lay committee 
members, who consider the ethical issues relating to patient 
involvement.
A researcher wanting to study migraine should consider the 
ethical issues when involving patients in the design and conduct 
of their study. Consider patient burden, equity and power, fair 
and respectful arrangements, confidentiality and the purpose, 
processes and consequences of any data collected or stored.
Involve patients in writing a grant application
Patients sit on research prioritisation committees and fund-
ing panels, alongside clinicians and academics, to decide which 
research is commissioned and which grants are awarded. See 
Supplementary File 2, Example 10. Many UK funding panels 
expect to read convincing and meaningful accounts of how 
patients have had an impact at key stages: preparatory work to 
inform the planned research; writing the application form 
particularly the lay summary; and the proposed PPI activity dur-
ing the study. Expect to be challenged if PPI appears tokenistic. 
It is important to consider the trade-offs between specifying a 
plan for PPI in a research protocol and building in some lexibility 
for change as the research progresses. This may be challenging 
in countries where regulatory approvals for amending protocols 
is time consuming.
Patients can help researchers to write the whole grant appli-
cation in an engaging, easy to understand language. The lay 
summary is often one of the irst sections in a grant applica-
tion that funding committee members read to gain an overview 
of the study. Reviewers like to understand exactly what study 
participants will experience from start to inish. Describe PPI 
clearly so that the reader understands who, why, how many, how 
often, what methods and what impact patients have already had 
on the grant application and will have in contributing to future 
research decisions. For example, decisions about recruitment 
methods, intervention delivery or components, which outcomes 
will be primary or secondary and how to collect data. It helps 
to use language precisely and to understand how involving, 
participating, collaborating, consulting and engaging with 
patients in research differ (Box 2).
A patient helping to write and edit a grant application can 
make it clear what will happen to patients who participate and 
how patients will be involved from study conception to 
dissemination of findings.
Plan future dissemination of findings
Patients can advise on how research might have an impact on 
health and health care beyond an academic audience. They 
often have in-depth knowledge of their condition and of on-line 
sources of information beyond that of academics and clinicians. 
They can help to write reports, blogs or summaries of ind-
ings creatively. See Supplementary File 2, Example 11. Offer-
ing participants a lay summary of the research indings is good 
practice. ‘Patients Included Charters’ provide accreditation for 
involving patients in conferences and in journal publications64 and 
GRIPP2 PPI reporting guidelines29,65 are available. Involvement 
of patients and the public is a critical component in successful 
implementation of research indings into healthcare, although 
evidence for best practice is limited3,66,67.
The grant application for a study about migraine may propose 
a public event with a charity to present the results of the study. 
Researchers and patient partners may give joint talks. Small 
group discussions with migraine patients can suggest ways to 
spread the news and change care.
Conclusion
This article provides a starting point for researchers and 
patient partners who are planning to seek funding for research. 
There is no current international consensus on best practice or ter-
minology and guidance is evolving across countries and research 
disciplines. A crucial distinction when gaining patient perspec-
tives is between patient involvement in research and patients 
participating by providing data in surveys, qualitative interviews 
or group discussions. The ethical governance implications differ 
particularly regarding data protection.
Researchers and patient partners can choose a wide range 
of different approaches to PPI and each study will require 
consideration of the optimal approach. Rigour is needed because 
patients’ lived experience and persuasive narratives can inluence 
important research decisions and the outcomes are not always 
predictable. Evidence is needed about how different methods 
of involving people can improve research decisions, healthcare 
outcomes and impact. A more collaborative and reciprocal 
partnership approach with patients has the potential to ensure that 
research undertaken matters to a wider tranche of society and 
involves those who stand most to beneit from it.
Key messages
Important questions for researchers about including PPI in their 
research:
•    How can I ind people in society (patients, patient groups, 
carers, the taxpaying public, lay organisations) who can 
make important contributions to research design, conduct 
and dissemination?
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•    How will PPI help me to access the perspectives of those 
who the research potentially will impact on?
•    How can different approaches to involving patients as 
consultants, collaborators or partners improve the relevance, 
quality, future implementation and sustainability of 
research?
•    How can patients contribute to three key functions: research 
decision-making; enhance researchers’ understanding of 
different perspectives; and knowledge capture?
•    How can PPI, qualitative research and surveys of patient 
opinion be optimally combined?
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